tbuckley/cabot-search huggingface dataset:
A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease
Authors: Scott H. Waddell, Yuelin Yao, Paula Olaizola, Alexander Walker, Edward J. Jarman, Konstantinos Gournopanos, Andreea Gradinaru, Ersi Christodoulou, Philippe Gautier, Melissa M. Boerrigter, Massimiliano Cadamuro, Luca Fabris, Joost PH Drenth, Timothy J. Kendall, Jesus M. Banales, Ava Khamseh, Pleasantine Mill, Luke Boulter
Journal: Science Translational Medicine (2023)

The formation of multiple cysts in the liver occurs in a number of isolated monogenic diseases or multisystemic syndromes, during which bile ducts develop into fluid-filled biliary cysts. For patients with polycystic liver disease (PCLD), nonsurgical treatments are limited, and managing life-long abdominal swelling, pain, and increasing risk of cyst rupture and infection is common. We demonstrate here that loss of the primary cilium on postnatal biliary epithelial cells (via the deletion of the cilia gene Wdr35 ) drives ongoing pathological remodeling of the biliary tree, resulting in progressive cyst formation and growth. The development of cystic tissue requires the activation of transforming growth factor–β (TGFβ) signaling, which promotes the expression of a procystic, fibronectin-rich extracellular matrix and which itself is perceived by a changing profile of integrin receptors on the cystic epithelium. This signaling axis is conserved in liver cysts from patients with either autosomal dominant polycystic kidney disease or autosomal dominant polycystic liver disease, indicating that there are common cellular mechanisms for liver cyst growth regardless of the underlying genetic cause. Cyst number and size can be reduced by inhibiting TGFβ signaling or integrin signaling in vivo. We suggest that our findings represent a therapeutic route for patients with polycystic liver disease, most of whom would not be amenable to surgery.
SHP2 promotes sarcoidosis severity by inhibiting SKP2-targeted ubiquitination of TBET in CD8 <sup>+</sup> T cells
Authors: Sherly I. Celada, Clarice X. Lim, Alexandre F. Carisey, Scott A. Ochsner, Carlos F. Arce Deza, Praveen Rexie, Fernando Poli De Frias, Rafael Cardenas-Castillo, Francesca Polverino, Markus Hengstschläger, Konstantin Tsoyi, Neil J. McKenna, Farrah Kheradmand, Thomas Weichhart, Ivan O. Rosas, Luc Van Kaer, Lindsay J. Celada
Journal: Science Translational Medicine (2023)

Sarcoidosis is an interstitial lung disease (ILD) characterized by interferon-γ (IFN-γ) and T-box expressed in T cells (TBET) dysregulation. Although one-third of patients progress from granulomatous inflammation to severe lung damage, the molecular mechanisms underlying this process remain unclear. Here, we found that pharmacological inhibition of phosphorylated SH2-containing protein tyrosine phosphatase-2 (pSHP2), a facilitator of aberrant IFN-γ abundance, decreased large granuloma formation and macrophage infiltration in the lungs of mice with sarcoidosis-like disease. Positive treatment outcomes were dependent on the effective enhancement of TBET ubiquitination within CD8 + T cells. Mechanistically, we identified a posttranslational modification pathway in which the E3 F-box protein S-phase kinase–associated protein 2 (SKP2) targets TBET for ubiquitination in T cells under normal conditions. However, this pathway was disrupted by aberrant pSHP2 signaling in CD8 + T cells from patients with progressive pulmonary sarcoidosis and end-stage disease. Ex vivo inhibition of pSHP2 in CD8 + T cells from patients with end-stage sarcoidosis enhanced TBET ubiquitination and suppressed IFN-γ and collagen synthesis. Therefore, these studies provided new mechanistic insights into the SHP2-dependent posttranslational regulation of TBET and identified SHP2 inhibition as a potential therapeutic intervention against severe sarcoidosis. Furthermore, these studies also suggest that the small-molecule SHP2 inhibitor SHP099 might be used as a therapeutic measure against human diseases linked to TBET or ubiquitination.
A microtubule stabilizer ameliorates protein pathogenesis and neurodegeneration in mouse models of repetitive traumatic brain injury
Authors: Xinyi Zhao, Wen Zeng, Hong Xu, Zihan Sun, Yingxin Hu, Beibei Peng, Jennifer D. McBride, Jiangtao Duan, Juan Deng, Bin Zhang, Soo-Jung Kim, Bryan Zoll, Takashi Saito, Hiroki Sasaguri, Takaomi C. Saido, Carlo Ballatore, Haishan Yao, Zhaoyin Wang, John Q. Trojanowski, Kurt R. Brunden, Virginia M.-Y. Lee, Zhuohao He
Journal: Science Translational Medicine (2023)

Tau pathogenesis is a hallmark of many neurodegenerative diseases, including Alzheimer’s disease (AD). Although the events leading to initial tau misfolding and subsequent tau spreading in patient brains are largely unknown, traumatic brain injury (TBI) may be a risk factor for tau-mediated neurodegeneration. Using a repetitive TBI (rTBI) paradigm, we report that rTBI induced somatic accumulation of phosphorylated and misfolded tau, as well as neurodegeneration across multiple brain areas in 7-month-old tau transgenic PS19 mice but not wild-type (WT) mice. rTBI accelerated somatic tau pathology in younger PS19 mice and WT mice only after inoculation with tau preformed fibrils and AD brain–derived pathological tau (AD-tau), respectively, suggesting that tau seeds are needed for rTBI-induced somatic tau pathology. rTBI further disrupted axonal microtubules and induced punctate tau and TAR DNA binding protein 43 (TDP-43) pathology in the optic tracts of WT mice. These changes in the optic tract were associated with a decline of visual function. Treatment with a brain-penetrant microtubule-stabilizing molecule reduced rTBI-induced tau, TDP-43 pathogenesis, and neurodegeneration in the optic tract as well as visual dysfunction. Treatment with the microtubule stabilizer also alleviated rTBI-induced tau pathology in the cortices of AD-tau–inoculated WT mice. These results indicate that rTBI facilitates abnormal microtubule organization, pathological tau formation, and neurodegeneration and suggest microtubule stabilization as a potential therapeutic avenue for TBI-induced neurodegeneration.
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy
Authors: Christian F Guerrero-Juarez, Parul K Goyal, Kyle T Amber
Journal: British Journal of Dermatology (2023)

The use of dupilumab has been suggested in the treatment of immune checkpoint inhibitor (ICI)-induced bullous pemphigoid. In this letter, we express caution with the targeted inhibition of the Th2 pathway given current evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, to ICI responses, particularly in melanoma.
Small Cell Carcinoma of the Ureter With Early Recurrence and Multiple Metastases Shown on 18F-FDG PET/CT
Authors: Zihao Tao, Yongkang Qiu, Wenpeng Huang, Aixiang Wang, Lei Kang
Journal: Clinical Nuclear Medicine (2023)

Primary small cell carcinoma of the ureter is an extremely rare malignancy with a poor prognosis. We present rare interesting 18 F-FDG PET/CT images of primary small cell carcinoma of the ureter in a 37-year-old man with early recurrence and multiple metastases 2 months after laparoscopic left nephroureterectomy and pelvic tumor resection. PET/CT showed high FDG-avid lesions in the pelvis, peritoneum, the left posterior wall of the bladder, and in the right lung, providing important value in the detection of recurrence and systemic metastases.
High-Risk Plaques on Coronary Computed Tomography Angiography
Authors: Daisuke Kinoshita, Keishi Suzuki, Eisuke Usui, Masahiro Hada, Haruhito Yuki, Takayuki Niida, Yoshiyasu Minami, Hang Lee, Iris McNulty, Junya Ako, Maros Ferencik, Tsunekazu Kakuta, Ik-Kyung Jang
Journal: JACC. Cardiovascular imaging (2023)
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF
Authors: Nitish K. Dhingra, Subodh Verma, Javed Butler, Stefan D. Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James L. Januzzi, Carolyn S.P. Lam, Naveed Sattar, Liliana Zaremba-Pechmann, Michael Böhm, Matias Nordaby, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, Milton Packer
Journal: JACC Heart Failure (2023)

The EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) trial established the efficacy of empagliflozin in reducing heart failure (HF) outcomes among patients with heart failure with reduced ejection fraction (HFrEF). The authors examined the outcomes of EMPEROR-Reduced as a function of background diuretic therapy. The EMPEROR-Reduced trial was a double-blind, randomized controlled trial of placebo vs empagliflozin 10 mg among 3,730 HFrEF patients. Herein, the population was stratified into 4 groups: no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. A total of 3,656 patients from the EMPEROR-Reduced trial were available for analysis. Of those patients, 482 (13.2%) were receiving no diuretic therapy, and 731 (20.0%), 1,411 (38.6%), and 1,032 (28.2%) were receiving <40 mg, 40 mg, and >40 mg, respectively. The efficacy of empagliflozin on the primary outcome (time to first event of hospitalization for HF or cardiovascular [CV] death) was consistent regardless of background diuretic therapy (>40 mg: HR: 0.88 [95% CI: 0.71-1.10]; 40 mg: HR: 0.65 [95% CI: 0.51-0.82]; <40 mg: HR: 0.65 [95% CI: 0.46-0.92]); no diuretic agents: HR: 0.78 [95% CI: 0.47-1.29]; Ptrend test = 0.192). Baseline diuretic doses did not influence the effect of empagliflozin on body weight, systolic blood pressure, NT-proBNP, or hematocrit at 52 weeks. The safety profile of empagliflozin vs placebo was unaffected by baseline diuretic dose; however, independently of treatment allocation, total rates of adverse events were higher among patients with higher baseline doses of diuretic agents. Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977)
Possible Causes and Clinical Relevance of a “Ring-Like” Late Gadolinium Enhancement Pattern
Authors: Michael Bietenbeck, Claudia Meier, Dennis Korthals, Maria Theofanidou, Philipp Stalling, Sven Dittmann, Eric Schulze-Bahr, Lars Eckardt, Ali Yilmaz
Journal: JACC. Cardiovascular imaging (2023)
Heart and Brain Changes in Acute Coronary Syndromes
Authors: Matthew G.L. Williams, Ngoc Jade Thai, Kate Liang, Estefania De Garate, Ronald Hartley-Davies, Christopher Lawton, Christelle Langley, Elanor C. Hinton, Chiara Bucciarelli-Ducci
Journal: JACC. Cardiovascular imaging (2023)
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation
Authors: Daniel Enríquez-Vázquez, Eduardo Barge-Caballero, Francisco González-Vílchez, Luis Almenar-Bonet, María Dolores García-Cosío Carmena, José González-Costello, Manuel Gómez-Bueno, María Ángeles Castel-Lavilla, Beatriz Díaz-Molina, Manuel Martínez-Sellés, Sonia Mirabet-Pérez, Luis De la Fuente-Galán, Daniela Hervás-Sotomayor, Diego Rangel-Sousa, Iris P. Garrido-Bravo, Teresa Blasco-Peiró, Gregorio Rábago Juan-Aracil, Javier Muñiz, María G. Crespo-Leiro
Journal: JACC Heart Failure (2023)
Predicted Deleterious Variants in Cardiomyopathy Genes Prognosticate Mortality and Composite Outcomes in the UK Biobank
Authors: Babken Asatryan, Ravi A. Shah, Ghaith Sharaf Dabbagh, Andrew P. Landstrom, Dawood Darbar, Mohammed Y. Khanji, Luis R. Lopes, Stefan van Duijvenboden, Daniele Muser, Aaron Mark Lee, Christopher M. Haggerty, Pankaj Arora, Christopher Semsarian, Tobias Reichlin, Virend K. Somers, Anjali T. Owens, Steffen E. Petersen, Rajat Deo, Patricia B. Munroe, Nay Aung, C. Anwar A. Chahal
Journal: JACC Heart Failure (2023)

Inherited cardiomyopathies present with broad variation of phenotype. Data are limited regarding genetic screening strategies and outcomes associated with predicted deleterious variants in cardiomyopathy-associated genes in the general population.
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3
Authors: Lu Zhang, Amy Kempf, Inga Nehlmeier, Anne Cossmann, Alexandra Dopfer-Jablonka, Metodi V Stankov, Sebastian R Schulz, Hans-Martin Jäck, Georg M N Behrens, Stefan Pöhlmann, Markus Hoffmann
Journal: The Lancet Infectious Diseases (2023)
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Authors: Gustavo H Dayan, Nadine Rouphael, Stephen R Walsh, Aiying Chen, Nicole Grunenberg, Mary Allen, Johannes Antony, Kwaku Poku Asante, Amit Suresh Bhate, Tatiana Beresnev, Matthew I Bonaparte, Médéric Celle, Maria Angeles Ceregido, Lawrence Corey, Dmytro Dobrianskyi, Bo Fu, Marie-Helene Grillet, Maryam Keshtkar-Jahromi, Michal Juraska, Jia Jin Kee, Hannah Kibuuka, Marguerite Koutsoukos, Roger Masotti, Nelson L Michael, Kathleen M Neuzil, Humberto Reynales, Merlin L Robb, Sandra M Villagómez Martínez, Fredrick Sawe, Lode Schuerman, Tina Tong, John Treanor, T Anh Wartel, Carlos A Diazgranados, Roman M Chicz, Sanjay Gurunathan, Stephen Savarino, Saranya Sridhar, Karina Abalos, Jose Accini, Naveena Aloysia, John Humphrey Amuasi, Nana Akosua Ansah, David Benkeser, Aude Berge, Hanna Beyko, Oleksandra Bilotkach, Thomas Breuer, Alberto Cadena Bonfanti, Elisabeth Bukusi, Richard Canter, Jaime Augusto Carrillo, Danaya Chansinghakul, Florence Coux, Chandan Das, Santa Kumar Das, Louis Devlin, Luis Espinoza, Michael Fay, Dean Follmann, Carina Frago, Agnes Garinga, Peter B Gilbert, Claudia Gonzalez, Maria Angelica Granados, Lea Guillery, Ying Huang, Kathy Hudzina, Manish Jain, Piush Kanodia, Nitin Khandelwal, Cissy Kityo Mutuluuza, Francis Kiweewa, Noah Kiwanuka, Chalit Kosolsak, Darshna Kukian, Jitendra Singh Kushwaha, Thelma Laot, Eduardo Lopez-Medina, Hugo Macareno Arroyo, Kishorchandra Mandaliya, Stephanie Mamod, Somnath Mangarule, Javier Martínez, Scott McClelland, Lisa Menard, Sandra Mendoza, Satyajit Mohapatra, Catherine Moreau, Nelly Mugo, Videlis Nduba, Fernando Noriega, Patricia Nahirya Ntege, Brenda Okech, Maria Otero, Samuel Gurrion Ouma, Janet Oyieko, Mercedes Paredes, Erwin Pardo, Svitlana Postol, David Pekala, Penny Peng, Marie-Laure Py, Enrique Rivas, Rafael Rivero, Edith Rodriguez, Mansoor Saleh, Pedro Sánchez, Nessryne Sater, Jinen Shah, Rajeev Shrestha, Abraham Siika, Chandramani Singh, Veer Bahadur Singh, Dipesh Tamrakar, Fernanda Tavares Da-Silva, Lucas Otieno Tina, Hector Velasquez, Deo Wabwire, Anne Wajja, Elodie Zaworski, Nianxian Zhang
Journal: The Lancet Respiratory Medicine (2023)
Long-term incidence of haematological cancer after bariatric surgery or usual care in the Swedish Obese Subjects study: a prospective cohort study
Authors: Kajsa Sjöholm, Johanna C Andersson-Assarsson, Felipe M Kristensson, Stephan Hjorth, Hege Gravdahl Garelius, Peter Jacobson, Per-Arne Svensson, Sofie Ahlin, Björn Carlsson, Markku Peltonen, Lena M S Carlsson, Magdalena Taube
Journal: The Lancet Healthy Longevity (2023)

Bariatric surgery in people with obesity is associated with a reduced overall cancer risk. Retrospective studies indicate that bariatric surgery specifically might reduce the risk of haematological cancers, but there is an absence of data from long-term, prospective studies. We therefore studied the association between bariatric surgery and haematological cancer in the Swedish Obese Subjects study.The prospective controlled Swedish Obese Subjects study was designed to compare overall mortality in people who underwent bariatric surgery (n=2007) and usual care (n=2040). Participants were recruited through campaigns in mass media and at 480 primary health-care centres all over Sweden. The inclusion criteria were an age of 37-60 years and a BMI of 34 kg/m2 or more in men and 38 kg/m2 or more in women before or at the time of the examination. Haematological cancer events, including malignant lymphoma, myeloma, myeloproliferative neoplasms, as well as acute and chronic leukaemias, were captured from the Swedish Cancer Registry. The main outcome of this study was haematological cancer incidence and mortality. This study is registered with ClinicalTrials.gov (NCT01479452) and is ongoing.A total of 4047 individuals with obesity were enrolled between Sept 1, 1987, and Jan 31, 2001. Overall, 34 participants in the surgery group and 51 participants in the usual care control group were diagnosed with haematological cancer during follow-up (hazard ratio [HR] 0·60; 95% CI 0·39-0·92; p=0·020). Moreover, there were three deaths by haematological cancer in the surgery group and 13 deaths in the control group (0·22; 0·06-0·76; p=0·017). Surgery was also associated with a reduced incidence of lymphoma (0·45; 0·23-0·88; p=0·020). A significant difference in treatment effect between men and women was found; bariatric surgery was associated with reduced incidence of haematological cancer in women (0·44; 0·26-0·74; p=0·002), but not in men (1·35; 0·58-3·17; p=0·489; interaction p=0·031).Bariatric surgery is associated with a reduced incidence of haematological cancer, specifically in women. Health-care providers and policy makers working in the field of cancer prevention should consider bariatric surgery a primary prevention resource for people with obesity.The Swedish Research Council, the Swedish State under the agreement between the Swedish Government and the county councils, the Avtal om Läkarutbildning och Forskning agreement, the Health & Medical Care Committee of the Region Västra Götaland, the Swedish Heart Lung Foundation, Gothenburg Medical Society, and the Adlerbert Research Foundation.For the Swedish translation of the abstract see Supplementary Material section.
SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
Authors: Kim Blom, Peter Fjällström, Christian Molnár, Mikael Åberg, Linnea Vikström, Julia Wigren-Byström, Louise Bennet, Micael Widerström, Gunlög Rasmussen, Jonas Klingström, Mattias N E Forsell, Anders F Johansson
Journal: The Lancet Infectious Diseases (2023)
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use
Authors: Lawrence Mbuagbaw, Cristian Garcia, Bluma Brenner, Diego Cecchini, Mohamed Chakroun, Pascal Djiadeu, Africa Holguin, Orna Mor, Neil Parkin, Maria M Santoro, Santiago Ávila-Ríos, Joseph Fokam, Andrew Phillips, Robert W Shafer, Michael R Jordan
Journal: The Lancet HIV (2023)
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Authors: Michael Reid, Yvan Jean Patrick Agbassi, Nimalan Arinaminpathy, Alyssa Bercasio, Anurag Bhargava, Madhavi Bhargava, Amy Bloom, Adithya Cattamanchi, Richard Chaisson, Daniel Chin, Gavin Churchyard, Helen Cox, Claudia M Denkinger, Lucica Ditiu, David Dowdy, Mark Dybul, Anthony Fauci, Endalkachew Fedaku, Mustapha Gidado, Mark Harrington, Janika Hauser, Petra Heitkamp, Nick Herbert, Ani Herna Sari, Philip Hopewell, Emily Kendall, Aamir Khan, Andrew Kim, Irene Koek, Sergiy Kondratyuk, Nalini Krishnan, Chu-Chang Ku, Erica Lessem, Erin V McConnell, Payam Nahid, Matt Oliver, Madhukar Pai, Mario Raviglione, Theresa Ryckman, Marco Schäferhoff, Sachin Silva, Peter Small, Guy Stallworthy, Zelalem Temesgen, Kitty van Weezenbeek, Anna Vassall, Gustavo E Velásquez, Nandita Venkatesan, Gavin Yamey, Armand Zimmerman, Dean Jamison, Soumya Swaminathan, Eric Goosby
Journal: The Lancet (2023)
Human PLCG2 haploinsufficiency results in a novel natural killer cell immunodeficiency
Authors: Joshua B. Alinger, Emily M. Mace, Justin.R. Porter, Annelise Y. Mah-Som, Allyssa L. Daugherty, Stephanie Li, Allison A. Throm, Jeanette T. Pingel, Nermina Saucier, Albert Yao, Ivan K. Chinn, James R. Lupski, Mohammad Ehlayel, Michael Keller, Greg R. Bowman, Megan A. Cooper, Jordan S. Orange, Anthony R. French
Journal: Journal of Allergy and Clinical Immunology (2023)
Psychosocial factors associated with camouflaging in autistic people and its relationship with mental health and well-being: A mixed methods systematic review
Authors: Sici Zhuang, Diana Weiting Tan, Susan Reddrop, Lydia Dean, Murray Maybery, Iliana Magiati
Journal: Clinical Psychology Review (2023)

Camouflaging involves hiding one's autistic characteristics in social situations. This mixed methods systematic review synthesized research on psychosocial factors associated with camouflaging and its relationship with mental well-being. Six databases were searched. The 58 included studies (40 qualitative, 13 quantitative, five mixed methods), encompassed 4808 autistic and 1780 non-autistic participants, and predominantly featured White, female, and late-diagnosed autistic adults with likely at least average intellectual and/or verbal abilities. Following a convergent integrated approach, quantitative data were transformed and synthesized with qualitative data for thematic synthesis. We identified three themes on psychosocial correlates of camouflaging: (1) social norms and pressures of a largely non-autistic world, (2) social acceptance and rejection, and (3) self-esteem and identity; and four themes on psychosocial consequences of camouflaging for well-being: (1) a pragmatic way of exerting individual agency and control; (2) overlooked, under-supported, and burnt out; (3) impact on social relationships; and (4) low self-esteem and identity confusion. Camouflaging emerges as primarily a socially motivated response linked to adverse psychosocial outcomes. A whole society approach towards acceptance and support for autistic individuals to express their authentic selves is needed. Future studies examining psychosocial influences on camouflaging should include participants who more broadly represent the autistic population.
Gut microbiome is associated with asthma and race in children with food allergy
Authors: Mahboobeh Mahdavinia, John P. Fyolek, Jialing Jiang, Neil Thivalapill, Lucy A. Bilaver, Christopher Warren, Susan Fox, Sai R. Nimmagadda, Pamela J. Newmark, Hemant Sharma, Amal Assa’ad, Patrick C. Seed, Ruchi S. Gupta
Journal: Journal of Allergy and Clinical Immunology (2023)
Selective Laser Trabeculoplasty for the Treatment of Glaucoma
Authors: Hana L. Takusagawa, Ambika Hoguet, Arthur J. Sit, Jullia A. Rosdahl, Vikas Chopra, Yvonne Ou, Grace Richter, Stephen J. Kim, Darrell WuDunn
Journal: Ophthalmology (2023)
Care Pathways and Initial Engagement in Early Psychosis Intervention Services Among Youths and Young Adults
Authors: Alexia Polillo, George Foussias, Wei Wang, Aristotle N. Voineskos, Jacqueline Veras, Nicole Davis-Faroque, Albert H.C. Wong, Nicole Kozloff
Journal: JAMA Network Open (2023)

Broad efforts to improve access to early psychosis intervention (EPI) services may not address health disparities in pathways to care and initial engagement in treatment.